Your browser doesn't support javascript.
loading
Mixed-Beam Approach for High-Risk Prostate Cancer Carbon-Ion Boost Followed by Photon Intensity-Modulated Radiotherapy: Preliminary Results of Phase II Trial AIRC-IG-14300.
Marvaso, Giulia; Vischioni, Barbara; Pepa, Matteo; Zaffaroni, Mattia; Volpe, Stefania; Patti, Filippo; Bellerba, Federica; Gandini, Sara; Comi, Stefania; Corrao, Giulia; Zerini, Dario; Augugliaro, Matteo; Fodor, Cristiana; Russo, Stefania; Molinelli, Silvia; Ciocca, Mario; Ricotti, Rosalinda; Valvo, Francesca; Giandini, Tommaso; Avuzzi, Barbara; Valdagni, Riccardo; De Cobelli, Ottavio; Cattani, Federica; Orlandi, Ester; Jereczek-Fossa, Barbara Alicja; Orecchia, Roberto.
Afiliação
  • Marvaso G; Division of Radiotherapy, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
  • Vischioni B; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Pepa M; Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
  • Zaffaroni M; Division of Radiotherapy, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
  • Volpe S; Division of Radiotherapy, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
  • Patti F; Division of Radiotherapy, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
  • Bellerba F; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Gandini S; Division of Radiotherapy, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
  • Comi S; Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
  • Corrao G; Department of Experimental Oncology, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
  • Zerini D; Department of Experimental Oncology, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
  • Augugliaro M; Medical Physics Unit, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
  • Fodor C; Division of Radiotherapy, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
  • Russo S; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Molinelli S; Division of Radiotherapy, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
  • Ciocca M; Division of Radiotherapy, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
  • Ricotti R; Division of Radiotherapy, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
  • Valvo F; Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
  • Giandini T; Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
  • Avuzzi B; Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
  • Valdagni R; Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
  • De Cobelli O; Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
  • Cattani F; Medical Physics Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy.
  • Orlandi E; Department of Radiation Oncology 1, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy.
  • Jereczek-Fossa BA; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Orecchia R; Department of Radiation Oncology 1, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy.
Front Oncol ; 11: 778729, 2021.
Article em En | MEDLINE | ID: mdl-34869026
ABSTRACT

PURPOSE:

This study represents a descriptive analysis of preliminary results of a Phase II trial on a novel mixed beam radiotherapy (RT) approach, consisting of carbon ions RT (CIRT) followed by intensity-modulated photon RT, in combination with hormonal therapy, for high-risk prostate cancer (HR PCa) with a special focus on acute toxicity.

METHODS:

Primary endpoint was the evaluation of safety in terms of acute toxicity. Secondary endpoints were early and long-term tolerability of treatment, quality of life (QoL), and efficacy. Data on acute and late toxicities were collected according to RTOG/EORTC. QoL of enrolled patients was assessed by IPSS, EORTC QLQ-C30, EORTC QLQ-PR25, and sexual activity by IIEF-5.

RESULTS:

Twenty-six patients were enrolled in the study, but only 15 completed so far the RT course and were included. Immediately after CIRT, no patients experienced GI/GU toxicity. At 1 and 3 months from the whole course RT completion, no GI/GU toxicities greater than grade 2 were observed. QoL scores were overall satisfactory.

CONCLUSIONS:

The feasibility of the proposed mixed treatment schedule was assessed, and an excellent acute toxicity profile was recorded. Such findings instil confidence in the continuation of this mixed approach, with evaluation of long-term tolerability and efficacy.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália